Exagen Inc.
XGN
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lā¦ read more
Healthcare
Diagnostics & Research
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.78
Price+4.71%
$0.35
1Y
Price
Market Cap
$187.963m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-11.9%
EBITDA Margin-22.9%
Net Profit Margin-61.5%
Free Cash Flow Margin-11.9%
EBITDA Margin-22.9%
Net Profit Margin-61.5%
Free Cash Flow MarginRevenue
$68.383m
+2.7%
1y CAGR+9.4%
3y CAGR+10.9%
5y CAGREarnings
-$20.166m
-1.1%
1y CAGR+1.0%
3y CAGR+13.3%
5y CAGREPS
-$0.90
+3.2%
1y CAGR+9.8%
3y CAGR+20.2%
5y CAGRBook Value
$14.432m
$51.957m
Assets$37.525m
Liabilities$25.354m
DebtDebt to Assets
48.8%
-2x
Debt to EBITDAFree Cash Flow
-$14.127m
+1.0%
1y CAGR+2.4%
3y CAGR+16.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company